iPSC-Derived Mesenchymal Stem Cells: Navigating the Transition to Xeno-Free Culture for Next Generation Regenerative Therapies
DOI:
https://doi.org/10.62146/ijecbe.v3i4.194Keywords:
Induced pluripotent stem cell (iPSC), Mesenchymal stem cell (MSC), Regenerative medicine, Stem cell, Xeno-free mediumAbstract
Mesenchymal stem cells (MSCs) are multipotent cells with the capacity to differentiate into mesodermal lineages and exhibit immunomodulatory and regenerative effects. Traditionally, MSCs can be isolated from bone marrow, adipose tissue, and umbilical cord. MSCs have shown various promising potentials. However, their therapeutic applications are still limited by several factors. Therefore, induced pluripotent stem cells (iPSCs) are developed to open new opportunities by enabling the generation of induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) that maintain the characteristics of MSCs while improving their potential, including proliferative potential. Furthermore, the development of xenofree and chemically defined media has improved safety and consistency by reducing the animal components. This review aims to summarize the biological characteristics of MSCs, highlight the xenofree and chemically defined medium, and outline their impacts on future clinical applications.
References
J. K. Biehl and B. Russell, “Introduction to Stem Cell Therapy,” Journal of Cardiovascular Nursing, vol. 24, no. 2, pp. 98–103, Mar. 2009, doi: 10.1097/JCN.0b013e318197a6a5.
Z. Wang et al., “Global scientific trends on the immunomodulation of mesenchymal stem cells in the 21st century: A bibliometric and visualized analysis,” Front Immunol, vol. 13, Aug. 2022, doi: 10.3389/fimmu.2022.984984.
J. Liu et al., “Mesenchymal stem cells and their microenvironment,” Stem Cell Res Ther, vol. 13, no. 1, p. 429, Aug. 2022, doi: 10.1186/s13287-022-02985-y.
K. Zha et al., “Recent Developed Strategies for Enhancing Chondrogenic Differentiation of MSC: Impact on MSC-Based Therapy for Cartilage Regeneration,” Stem Cells Int, vol. 2021, pp. 1–15, Mar. 2021, doi: 10.1155/2021/8830834.
M. Fakhry, “Molecular mechanisms of mesenchymal stem cell differentiation towards osteoblasts,” World J Stem Cells, vol. 5, no. 4, p. 136, 2013, doi: 10.4252/wjsc.v5.i4.136.
Z. Mohammadi et al., “Differentiation of adipocytes and osteocytes from human adipose and placental mesenchymal stem cells.”
R. Mei et al., “Advances and clinical challenges of mesenchymal stem cell therapy,” Front Immunol, vol. 15, Jul. 2024, doi: 10.3389/fimmu.2024.1421854.
R. Secunda, R. Vennila, A. M. Mohanashankar, M. Rajasundari, S. Jeswanth, and R. Surendran, “Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study,” Cytotechnology, vol. 67, no. 5, pp. 793–807, Oct. 2015, doi: 10.1007/s10616-014-9718-z.
R. Newman, D. Yoo, M. LeRoux, and A. Danilkovitch-Miagkova, “Treatment of Inflammatory Diseases with Mesenchymal Stem Cells,” Inflamm Allergy Drug Targets, vol. 8, no. 2, pp. 110–123, Jun. 2009, doi: 10.2174/187152809788462635.
K. Thanaskody, A. S. Jusop, G. J. Tye, W. S. Wan Kamarul Zaman, S. A. Dass, and F. Nordin, “MSCs vs. iPSCs: Potential in therapeutic applications,” Front Cell Dev Biol, vol. 10, Nov. 2022, doi: 10.3389/fcell.2022.1005926.
W. Li et al., “Natural compounds and mesenchymal stem cells: implications for inflammatory-impaired tissue regeneration,” Stem Cell Res Ther, vol. 15, no. 1, p. 34, Feb. 2024, doi: 10.1186/s13287-024-03641-3.
D.-C. Ding, W.-C. Shyu, and S.-Z. Lin, “Mesenchymal Stem Cells,” Cell Transplant, vol. 20, no. 1, pp. 5–14, Feb. 2011, doi: 10.3727/096368910X.
B. Chen, Z. Chen, M. He, L. Zhang, L. Yang, and L. Wei, “Recent advances in the role of mesenchymal stem cells as modulators in autoinflammatory diseases,” Front Immunol, vol. 15, Dec. 2024, doi: 10.3389/fimmu.2024.1525380.
M. S. Choudhery et al., “Induced Mesenchymal Stem Cells: An Emerging Source for Regenerative Medicine Applications,” J Clin Med, vol. 14, no. 6, p. 2053, Mar. 2025, doi: 10.3390/jcm14062053.
Z. Wu et al., “Induced pluripotent stem cell-derived mesenchymal stem cells: whether they can become new stars of cell therapy,” Stem Cell Res Ther, vol. 15, no. 1, p. 367, Oct. 2024, doi: 10.1186/s13287-024-03968-x.
D. Sheyn et al., “Human Induced Pluripotent Stem Cells Differentiate Into Functional Mesenchymal Stem Cells and Repair Bone Defects,” Stem Cells Transl Med, vol. 5, no. 11, pp. 1447–1460, Nov. 2016, doi: 10.5966/sctm.2015-0311.
A. S. Monzel et al., “Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells,” Stem Cell Reports, vol. 8, no. 5, pp. 1144–1154, May 2017, doi: 10.1016/j.stemcr.2017.03.010.
F. Soldner and R. Jaenisch, “iPSC Disease Modeling,” Science (1979), vol. 338, no. 6111, pp. 1155–1156, Nov. 2012, doi: 10.1126/science.1227682.
T. Pozner, C. Grandizio, M. W. Mitchell, N. Turan, and L. Scheinfeldt, “Human iPSC Reprogramming Success: The Impact of Approaches and Source Materials,” Stem Cells Int, vol. 2025, no. 1, Jan. 2025, doi: 10.1155/sci/2223645.
S. Daubman, “Landmark Approach to Generating Human Stem Cells,” Circ Res, vol. 108, no. 2, pp. 161–163, Jan. 2011, doi: 10.1161/RES.0b013e31820d7dd1.
V. Sabapathy and S. Kumar, “hiPSC‐derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine,” J Cell Mol Med, vol. 20, no. 8, pp. 1571–1588, Aug. 2016, doi: 10.1111/jcmm.12839.
C. D. S. J. X. T. K. F. R. J. N. Sümeyra Naz Usta, “Chemically defined serum-free and xeno-free media for multiple cell lineages,” Ann Transl Med, vol. 2, no. 10, p. 97, 2014.
J. Xu, W. Lian, J. Chen, W. Li, L. Li, and Z. Huang, “Chemical-defined medium supporting the expansion of human mesenchymal stem cells,” Stem Cell Res Ther, vol. 11, no. 1, p. 125, Dec. 2020, doi: 10.1186/s13287-020-01641-7.
D. Salzig, J. Leber, K. Merkewitz, M. C. Lange, N. Köster, and P. Czermak, “Attachment, Growth, and Detachment of Human Mesenchymal Stem Cells in a Chemically Defined Medium,” Stem Cells Int, vol. 2016, no. 1, Jan. 2016, doi: 10.1155/2016/5246584.
A. Srinivasan et al., “Human Platelet Releasate (hPR) - A xeno-free supplement for the expansion of stem cells,” Cytotherapy, vol. 22, no. 5, pp. S39–S40, May 2020, doi: 10.1016/j.jcyt.2020.03.036.
K. Stefańska, R. Bryl, L. Moncrieff, N. Pinto, J. A. Shibli, and M. Dyszkiewicz-Konwińska, “Mesenchymal stem cells – a historical overview,” Medical Journal of Cell Biology, vol. 8, no. 2, pp. 83–87, Sep. 2020, doi: 10.2478/acb-2020-0010.
H. Rayat Pisheh and M. Sani, “Mesenchymal stem cells derived exosomes: a new era in cardiac regeneration,” Stem Cell Res Ther, vol. 16, no. 1, p. 16, Jan. 2025, doi: 10.1186/s13287-024-04123-2.
C. M. Trigo, J. S. Rodrigues, S. P. Camões, S. Solá, and J. P. Miranda, “Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?,” J Adv Res, vol. 70, pp. 103–124, Apr. 2025, doi: 10.1016/j.jare.2024.05.004.
K. Stefańska, R. Bryl, G. Hutchings, J. A. Shibli, and M. Dyszkiewicz-Konwińska, “Human umbilical cord stem cells – the discovery, history and possible application,” Medical Journal of Cell Biology, vol. 8, no. 2, pp. 78–82, Sep. 2020, doi: 10.2478/acb-2020-0009.
Y. Wang et al., “Mesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease,” Front Cell Dev Biol, vol. 9, Jan. 2022, doi: 10.3389/fcell.2021.742088.
U. Švajger, K. Zajc, A. B. Česnik, and K. Hartman, “Pooled umbilical cord-derived MSCs retain key phenotypic and immunomodulatory properties – A path toward consistent manufacturing,” Tissue Cell, vol. 96, p. 103036, Oct. 2025, doi: 10.1016/j.tice.2025.103036.
E. H. de Laorden et al., “Human placenta-derived mesenchymal stem cells stimulate neuronal regeneration by promoting axon growth and restoring neuronal activity,” Front Cell Dev Biol, vol. 11, Dec. 2023, doi: 10.3389/fcell.2023.1328261.
Q. Huang et al., “An efficient protocol to generate placental chorionic plate-derived mesenchymal stem cells with superior proliferative and immunomodulatory properties,” Stem Cell Res Ther, vol. 10, no. 1, p. 301, Dec. 2019, doi: 10.1186/s13287-019-1405-8.
P. A. Zuk et al., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Eng, vol. 7, no. 2, pp. 211–228, Apr. 2001, doi: 10.1089/107632701300062859.
P. Zuk, “Adipose-Derived Stem Cells in Tissue Regeneration: A Review,” ISRN Stem Cells, vol. 2013, pp. 1–35, Feb. 2013, doi: 10.1155/2013/713959.
S. S. Moonshi, H. Adelnia, Y. Wu, and H. T. Ta, “Placenta‐Derived Mesenchymal Stem Cells for Treatment of Diseases: A Clinically Relevant Source,” Adv Ther (Weinh), vol. 5, no. 10, Oct. 2022, doi: 10.1002/adtp.202200054.
C. Pipino et al., “Placenta as a reservoir of stem cells: an underutilized resource?,” Br Med Bull, vol. 105, no. 1, pp. 43–68, Mar. 2013, doi: 10.1093/bmb/lds033.
S. Chetty et al., “Umbilical cord mesenchymal stromal cells—from bench to bedside,” Front Cell Dev Biol, vol. 10, Oct. 2022, doi: 10.3389/fcell.2022.1006295.
E. Gluckman et al., “Hematopoietic Reconstitution in a Patient with Fanconi’s Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling,” New England Journal of Medicine, vol. 321, no. 17, pp. 1174–1178, Oct. 1989, doi: 10.1056/NEJM198910263211707.
T. Nagamura-Inoue, “Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility,” World J Stem Cells, vol. 6, no. 2, p. 195, 2014, doi: 10.4252/wjsc.v6.i2.195.
E. Ledesma-Martínez, V. M. Mendoza-Núñez, and E. Santiago-Osorio, “Mesenchymal Stem Cells Derived from Dental Pulp: A Review,” Stem Cells Int, vol. 2016, no. 1, Jan. 2016, doi: 10.1155/2016/4709572.
V. J. Costela-Ruiz et al., “Different Sources of Mesenchymal Stem Cells for Tissue Regeneration: A Guide to Identifying the Most Favorable One in Orthopedics and Dentistry Applications,” Int J Mol Sci, vol. 23, no. 11, p. 6356, Jun. 2022, doi: 10.3390/ijms23116356.
S. Gronthos, M. Mankani, J. Brahim, P. G. Robey, and S. Shi, “Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo,” Proceedings of the National Academy of Sciences, vol. 97, no. 25, pp. 13625–13630, Dec. 2000, doi: 10.1073/pnas.240309797.
B. Sui, D. Wu, L. Xiang, Y. Fu, X. Kou, and S. Shi, “Dental Pulp Stem Cells: From Discovery to Clinical Application,” J Endod, vol. 46, no. 9, pp. S46–S55, Sep. 2020, doi: 10.1016/j.joen.2020.06.027.
J. Wu et al., “Natural bioactive compounds modified with mesenchymal stem cells: new hope for regenerative medicine,” Front Bioeng Biotechnol, vol. 13, May 2025, doi: 10.3389/fbioe.2025.1446537.
C. De Bari, F. Dell’Accio, P. Tylzanowski, and F. P. Luyten, “Multipotent mesenchymal stem cells from adult human synovial membrane,” Arthritis Rheum, vol. 44, no. 8, pp. 1928–1942, Aug. 2001, doi: 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.
N. Li et al., “Synovial membrane mesenchymal stem cells: past life, current situation, and application in bone and joint diseases,” Stem Cell Res Ther, vol. 11, no. 1, p. 381, Dec. 2020, doi: 10.1186/s13287-020-01885-3.
S. PATKI, S. KADAM, V. CHANDRA, and R. BHONDE, “Human breast milk is a rich source of multipotent mesenchymal stem cells,” Hum Cell, vol. 23, no. 2, pp. 35–40, May 2010, doi: 10.1111/j.1749-0774.2010.00083.x.
M. Sani et al., “Origins of the breast milk‐derived cells; an endeavor to find the cell sources,” Cell Biol Int, vol. 39, no. 5, pp. 611–618, May 2015, doi: 10.1002/cbin.10432.
Q. Wu et al., “Human menstrual blood-derived stem cells promote functional recovery in a rat spinal cord hemisection model,” Cell Death Dis, vol. 9, no. 9, p. 882, Aug. 2018, doi: 10.1038/s41419-018-0847-8.
X. Meng et al., “Endometrial regenerative cells: A novel stem cell population,” J Transl Med, vol. 5, no. 1, p. 57, Dec. 2007, doi: 10.1186/1479-5876-5-57.
N. Eiró et al., “Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells,” Oncotarget, vol. 5, no. 21, pp. 10692–10708, Nov. 2014, doi: 10.18632/oncotarget.2530.
N. Eiro et al., “Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer,” Stem Cell Res Ther, vol. 15, no. 1, p. 121, Apr. 2024, doi: 10.1186/s13287-024-03717-0.
M. Kou et al., “Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?,” Cell Death Dis, vol. 13, no. 7, p. 580, Jul. 2022, doi: 10.1038/s41419-022-05034-x.
S. Lim and B. Khoo, “An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy (Review),” Oncol Lett, vol. 22, no. 5, p. 785, Sep. 2021, doi: 10.3892/ol.2021.13046.
G. Pasquinelli et al., “Multidistrict human mesenchymal vascular cells: pluripotency and stemness characteristics,” Cytotherapy, vol. 12, no. 3, pp. 275–287, Jan. 2010, doi: 10.3109/14653241003596679.
X. Han et al., “Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies,” Signal Transduct Target Ther, vol. 10, no. 1, p. 262, Aug. 2025, doi: 10.1038/s41392-025-02313-9.
Z. Li, X. Hu, and J. F. Zhong, “Mesenchymal Stem Cells: Characteristics, Function, and Application,” Stem Cells Int, vol. 2019, pp. 1–2, Mar. 2019, doi: 10.1155/2019/8106818.
N. Song, M. Scholtemeijer, and K. Shah, “Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential,” Trends Pharmacol Sci, vol. 41, no. 9, pp. 653–664, Sep. 2020, doi: 10.1016/j.tips.2020.06.009.
W. Jiang and J. Xu, “Immune modulation by mesenchymal stem cells,” Cell Prolif, vol. 53, no. 1, Jan. 2020, doi: 10.1111/cpr.12712.
K. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell, vol. 126, no. 4, pp. 663–676, Aug. 2006, doi: 10.1016/j.cell.2006.07.024.
K. Takahashi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, vol. 131, no. 5, pp. 861–872, Nov. 2007, doi: 10.1016/j.cell.2007.11.019.
J. Yu et al., “Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells,” Science (1979), vol. 318, no. 5858, pp. 1917–1920, Dec. 2007, doi: 10.1126/science.1151526.
J. Cerneckis, H. Cai, and Y. Shi, “Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications,” Signal Transduct Target Ther, vol. 9, no. 1, p. 112, Apr. 2024, doi: 10.1038/s41392-024-01809-0.
M. A. Lancaster et al., “Cerebral organoids model human brain development and microcephaly,” Nature, vol. 501, no. 7467, pp. 373–379, Sep. 2013, doi: 10.1038/nature12517.
M. Dominici et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006, doi: 10.1080/14653240600855905.
Z. Wu et al., “Induced pluripotent stem cell-derived mesenchymal stem cells: whether they can become new stars of cell therapy,” Stem Cell Res Ther, vol. 15, no. 1, p. 367, Oct. 2024, doi: 10.1186/s13287-024-03968-x.
H.-R. Lee et al., “iPSC-Derived MSCs Are a Distinct Entity of MSCs with Higher Therapeutic Potential than Their Donor-Matched Parental MSCs,” Int J Mol Sci, vol. 24, no. 1, p. 881, Jan. 2023, doi: 10.3390/ijms24010881.
E. Fernandez-Rebollo et al., “Senescence-Associated Metabolomic Phenotype in Primary and iPSC-Derived Mesenchymal Stromal Cells,” Stem Cell Reports, vol. 14, no. 2, pp. 201–209, Feb. 2020, doi: 10.1016/j.stemcr.2019.12.012.
X.-L. Fan et al., “Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF-κB in allergic rhinitis patients,” Stem Cell Res Ther, vol. 9, no. 1, p. 170, Dec. 2018, doi: 10.1186/s13287-018-0896-z.
J. Park et al., “Mitochondrial genome mutations in mesenchymal stem cells derived from human dental induced pluripotent stem cells,” BMB Rep, vol. 52, no. 12, pp. 689–694, Dec. 2019, doi: 10.5483/BMBRep.2019.52.12.045.
Q. Wu, B. Yang, C. Cao, K. Hu, P. Wang, and Y. Man, “Therapeutic antibody directed osteogenic differentiation of induced pluripotent stem cell derived MSCs,” Acta Biomater, vol. 74, pp. 222–235, Jul. 2018, doi: 10.1016/j.actbio.2018.05.028.
E.-T. Tsai et al., “HLA-Homozygous iPSC-Derived Mesenchymal Stem Cells Rescue Rotenone-Induced Experimental Leber’s Hereditary Optic Neuropathy-like Models In Vitro and In Vivo,” Cells, vol. 12, no. 22, p. 2617, Nov. 2023, doi: 10.3390/cells12222617.
X. Liang et al., “Conditioned medium from induced pluripotent stem cell-derived mesenchymal stem cells accelerates cutaneous wound healing through enhanced angiogenesis,” Stem Cell Res Ther, vol. 12, no. 1, p. 295, Dec. 2021, doi: 10.1186/s13287-021-02366-x.
S. Kim, S. Lee, H. Kim, and T. Kim, “Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Accelerate Skin Cell Proliferation,” Int J Mol Sci, vol. 19, no. 10, p. 3119, Oct. 2018, doi: 10.3390/ijms19103119.
J. C. Buitrago et al., “Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles,” Sci Rep, vol. 14, no. 1, p. 24098, Oct. 2024, doi: 10.1038/s41598-024-75956-3.
P. Wang et al., “Mesenchymal Stem Cells Derived from Human Urine-Derived iPSCs Exhibit Low Immunogenicity and Reduced Immunomodulatory Profile,” Int J Mol Sci, vol. 25, no. 19, p. 10394, Sep. 2024, doi: 10.3390/ijms251910394.
S. Rajasingh et al., “Comparative analysis of human induced pluripotent stem cell‐derived mesenchymal stem cells and umbilical cord mesenchymal stem cells,” J Cell Mol Med, vol. 25, no. 18, pp. 8904–8919, Sep. 2021, doi: 10.1111/jcmm.16851.
H.-R. Lee et al., “iPSC-Derived MSCs Are a Distinct Entity of MSCs with Higher Therapeutic Potential than Their Donor-Matched Parental MSCs,” Int J Mol Sci, vol. 24, no. 1, p. 881, Jan. 2023, doi: 10.3390/ijms24010881.
D. Wang, Y.-Q. Sun, W.-X. Gao, X.-L. Fan, J.-B. Shi, and Q.-L. Fu, “An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells,” Cell Transplant, vol. 27, no. 9, pp. 1340–1351, Sep. 2018, doi: 10.1177/0963689718780194.
F. Umrath, M. Weber, S. Reinert, H.-P. Wendel, M. Avci-Adali, and D. Alexander, “iPSC-Derived MSCs Versus Originating Jaw Periosteal Cells: Comparison of Resulting Phenotype and Stem Cell Potential,” Int J Mol Sci, vol. 21, no. 2, p. 587, Jan. 2020, doi: 10.3390/ijms21020587.
K. Subbiahanadar Chelladurai et al., “Alternative to FBS in animal cell culture - An overview and future perspective,” Heliyon, vol. 7, no. 8, p. e07686, Aug. 2021, doi: 10.1016/j.heliyon.2021.e07686.
S. Shanbhag, A. Stavropoulos, S. Suliman, T. Hervig, and K. Mustafa, “Efficacy of Humanized Mesenchymal Stem Cell Cultures for Bone Tissue Engineering: A Systematic Review with a Focus on Platelet Derivatives,” Tissue Eng Part B Rev, vol. 23, no. 6, pp. 552–569, Dec. 2017, doi: 10.1089/ten.teb.2017.0093.
Y. Zhang, L. Wang, M. Yang, L. Huang, and H. Hu, “[Experimental study on culture of human mesenchymal stem cells from cord blood using autologous serum].,” Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, vol. 25, no. 5, pp. 1155–60, Oct. 2008.
S. Jung, A. Sen, L. Rosenberg, and L. A. Behie, “Human mesenchymal stem cell culture: rapid and efficient isolation and expansion in a defined serum-free medium,” J Tissue Eng Regen Med, vol. 6, no. 5, pp. 391–403, May 2012, doi: 10.1002/term.441.
X. Sun, Y. Gan, T. Tang, X. Zhang, and K. Dai, “In Vitro Proliferation and Differentiation of Human Mesenchymal Stem Cells Cultured in Autologous Plasma Derived from Bone Marrow,” Tissue Eng Part A, vol. 14, no. 3, pp. 391–400, Mar. 2008, doi: 10.1089/tea.2006.0429.
J. L. Berlier et al., “Adenosine Triphosphate Prevents Serum Deprivation-Induced Apoptosis in Human Mesenchymal Stem Cells via Activation of the MAPK Signaling Pathways,” Stem Cells, vol. 33, no. 1, pp. 211–218, Jan. 2015, doi: 10.1002/stem.1831.
Z. Xue-juan et al., “A comparative study on serum-free and serum culture methods of human umbilical cord mecenchymal stem cells,” Journal of Clinical Rehabilitative Tissue Engineering Research, vol. 22, no. 13, 2018.
L. Johansson, J. Klinth, O. Holmqvist, and S. Ohlson, “Platelet lysate: a replacement for fetal bovine serum in animal cell culture?,” Cytotechnology, vol. 42, no. 2, pp. 67–74, Jul. 2003, doi: 10.1023/B:CYTO.0000009820.72920.cf.
C. Doucet et al., “Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications,” J Cell Physiol, vol. 205, no. 2, pp. 228–236, Nov. 2005, doi: 10.1002/jcp.20391.
S. Palombella et al., “Systematic review and meta-analysis on the use of human platelet lysate for mesenchymal stem cell cultures: comparison with fetal bovine serum and considerations on the production protocol,” Stem Cell Res Ther, vol. 13, no. 1, p. 142, Apr. 2022, doi: 10.1186/s13287-022-02815-1.
V. Becherucci et al., “Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience,” Stem Cell Res Ther, vol. 9, no. 1, p. 124, Dec. 2018, doi: 10.1186/s13287-018-0863-8.
N.-C. Cheng, Y.-K. Tu, N.-H. Lee, and T.-H. Young, “Influence of Human Platelet Lysate on Extracellular Matrix Deposition and Cellular Characteristics in Adipose-Derived Stem Cell Sheets,” Front Cell Dev Biol, vol. 8, Oct. 2020, doi: 10.3389/fcell.2020.558354.
O. F. W. Gardner et al., “Human platelet lysate enhances proliferation but not chondrogenic differentiation of pediatric mesenchymal progenitors,” Cytotherapy, vol. 25, no. 3, pp. 286–297, Mar. 2023, doi: 10.1016/j.jcyt.2022.11.007.
J. Y. Lee et al., “Comparative analysis of mesenchymal stem cells cultivated in serum free media,” Sci Rep, vol. 12, no. 1, p. 8620, May 2022, doi: 10.1038/s41598-022-12467-z.
T. Burnouf, D. Strunk, M. B. C. Koh, and K. Schallmoser, “Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?,” Biomaterials, vol. 76, pp. 371–387, Jan. 2016, doi: 10.1016/j.biomaterials.2015.10.065.
S. M. Jonsdottir-Buch, R. Lieder, and O. E. Sigurjonsson, “Platelet Lysates Produced from Expired Platelet Concentrates Support Growth and Osteogenic Differentiation of Mesenchymal Stem Cells,” PLoS One, vol. 8, no. 7, p. e68984, Jul. 2013, doi: 10.1371/journal.pone.0068984.
H. Abdelrazik, G. M. Spaggiari, L. Chiossone, and L. Moretta, “Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and function,” Eur J Immunol, vol. 41, no. 11, pp. 3281–3290, Nov. 2011, doi: 10.1002/eji.201141542.
K. Tateishi et al., “Comparison of Human Serum with Fetal Bovine Serum for Expansion and Differentiation of Human Synovial MSC: Potential Feasibility for Clinical Applications,” Cell Transplant, vol. 17, no. 5, pp. 549–557, May 2008, doi: 10.3727/096368908785096024.
A. Shahdadfar, K. Frønsdal, T. Haug, F. P. Reinholt, and J. E. Brinchmann, “In Vitro Expansion of Human Mesenchymal Stem Cells: Choice of Serum Is a Determinant of Cell Proliferation, Differentiation, Gene Expression, and Transcriptome Stability,” Stem Cells, vol. 23, no. 9, pp. 1357–1366, Oct. 2005, doi: 10.1634/stemcells.2005-0094.
T. Kobayashi et al., “Motility and growth of human bone-marrow mesenchymal stem cells during ex vivo expansion in autologous serum,” J Bone Joint Surg Br, vol. 87-B, no. 10, pp. 1426–1433, Oct. 2005, doi: 10.1302/0301-620X.87B10.16160.
P. A. Sotiropoulou, S. A. Perez, M. Salagianni, C. N. Baxevanis, and M. Papamichail, “Cell Culture Medium Composition and Translational Adult Bone Marrow‐Derived Stem Cell Research,” Stem Cells, vol. 24, no. 5, pp. 1409–1410, May 2006, doi: 10.1634/stemcells.2005-0654.
N. Fekete et al., “Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components,” Cytotherapy, vol. 14, no. 5, pp. 540–554, May 2012, doi: 10.3109/14653249.2012.655420.
L. C. Garbin and C. S. Olver, “Platelet-Rich Products and Their Application to Osteoarthritis,” J Equine Vet Sci, vol. 86, p. 102820, Mar. 2020, doi: 10.1016/j.jevs.2019.102820.
A. É. Silva-Carvalho, F. A. R. Neves, and F. Saldanha-Araujo, “The immunosuppressive mechanisms of mesenchymal stem cells are differentially regulated by platelet poor plasma and fetal bovine serum supplemented media,” Int Immunopharmacol, vol. 79, p. 106172, Feb. 2020, doi: 10.1016/j.intimp.2019.106172.
M.-S. Lee et al., “Enhanced Cell Growth of Adipocyte-Derived Mesenchymal Stem Cells Using Chemically-Defined Serum-Free Media,” Int J Mol Sci, vol. 18, no. 8, p. 1779, Aug. 2017, doi: 10.3390/ijms18081779.
J. Xu, W. Lian, J. Chen, W. Li, L. Li, and Z. Huang, “Chemical-defined medium supporting the expansion of human mesenchymal stem cells,” Stem Cell Res Ther, vol. 11, no. 1, p. 125, Dec. 2020, doi: 10.1186/s13287-020-01641-7.
P. J. Dolley-Sonneville, L. E. Romeo, and Z. K. Melkoumian, “Synthetic Surface for Expansion of Human Mesenchymal Stem Cells in Xeno-Free, Chemically Defined Culture Conditions,” PLoS One, vol. 8, no. 8, p. e70263, Aug. 2013, doi: 10.1371/journal.pone.0070263.
K. McElearney, A. Ali, A. Gilbert, R. Kshirsagar, and L. Zang, “Tryptophan oxidation catabolite, N -formylkynurenine, in photo degraded cell culture medium results in reduced cell culture performance,” Biotechnol Prog, vol. 32, no. 1, pp. 74–82, Jan. 2016, doi: 10.1002/btpr.2198.
G. Schepici, A. Gugliandolo, and E. Mazzon, “Serum-Free Cultures: Could They Be a Future Direction to Improve Neuronal Differentiation of Mesenchymal Stromal Cells?,” Int J Mol Sci, vol. 23, no. 12, p. 6391, Jun. 2022, doi: 10.3390/ijms23126391.
S. Soontararak et al., “Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model,” Stem Cells Transl Med, vol. 7, no. 6, pp. 456–467, Jun. 2018, doi: 10.1002/sctm.17-0305.
M. Xu, G. Shaw, M. Murphy, and F. Barry, “Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells Are Functionally and Genetically Different From Bone Marrow-Derived Mesenchymal Stromal Cells,” Stem Cells, vol. 37, no. 6, pp. 754–765, Jun. 2019, doi: 10.1002/stem.2993.
A. K. Zhou et al., “Using Pre-Clinical Studies to Explore the Potential Clinical Uses of Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem cells,” Tissue Eng Regen Med, vol. 20, no. 6, pp. 793–809, Oct. 2023, doi: 10.1007/s13770-023-00557-6.
M.-S. Lee et al., “Autologous iPSC- and MSC-derived chondrocyte implants for cartilage repair in a miniature pig model,” Stem Cell Res Ther, vol. 16, no. 1, p. 86, Feb. 2025, doi: 10.1186/s13287-025-04215-7.
G. Hu et al., “Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice,” Stem Cell Res Ther, vol. 6, no. 1, p. 10, Apr. 2015, doi: 10.1186/scrt546.
Q. Lian et al., “Functional Mesenchymal Stem Cells Derived From Human Induced Pluripotent Stem Cells Attenuate Limb Ischemia in Mice,” Circulation, vol. 121, no. 9, pp. 1113–1123, Mar. 2010, doi: 10.1161/CIRCULATIONAHA.109.898312.
X. Li et al., “Mitochondrial Transfer of Induced Pluripotent Stem Cell–Derived Mesenchymal Stem Cells to Airway Epithelial Cells Attenuates Cigarette Smoke–Induced Damage,” Am J Respir Cell Mol Biol, vol. 51, no. 3, pp. 455–465, Sep. 2014, doi: 10.1165/rcmb.2013-0529OC.
H. Yang et al., “Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-α-stimulated gene-6 in inflammatory bowel disease models,” Cell Death Dis, vol. 10, no. 10, p. 718, Sep. 2019, doi: 10.1038/s41419-019-1957-7.
H. Kim et al., “Pan PPAR agonist stimulation of induced MSCs produces extracellular vesicles with enhanced renoprotective effect for acute kidney injury,” Stem Cell Res Ther, vol. 15, no. 1, p. 9, Jan. 2024, doi: 10.1186/s13287-023-03577-0.
P. Jungbluth et al., “Human iPSC-derived iMSCs improve bone regeneration in mini-pigs,” Bone Res, vol. 7, no. 1, p. 32, Oct. 2019, doi: 10.1038/s41413-019-0069-4.
A. J. C. Bloor et al., “Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study,” Nat Med, vol. 26, no. 11, pp. 1720–1725, Nov. 2020, doi: 10.1038/s41591-020-1050-x.
T. Winston et al., “Lineage‐Specific Mesenchymal Stromal Cells Derived from Human iPSCs Showed Distinct Patterns in Transcriptomic Profile and Extracellular Vesicle Production,” Advanced Science, vol. 11, no. 28, Jul. 2024, doi: 10.1002/advs.202308975.
P. Mohite et al., “Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies,” International Journal of Surgery, vol. 110, no. 10, pp. 6432–6455, Oct. 2024, doi: 10.1097/JS9.0000000000001892.
S. Yasuda et al., “Detection of residual pluripotent stem cells in cell therapy products utilizing droplet digital PCR: an international multisite evaluation study,” Stem Cells Transl Med, vol. 13, no. 10, pp. 1001–1014, Oct. 2024, doi: 10.1093/stcltm/szae058.
C. A. de Mortier et al., “Challenges and Stimulating Factors for the Incorporation of Economic Considerations in Clinical Practice Guidelines: A Scoping Review,” J Eval Clin Pract, vol. 31, no. 1, Feb. 2025, doi: 10.1111/jep.14264.
X. Zhou et al., “The application potential of iMSCs and iMSC-EVs in diseases,” Front Bioeng Biotechnol, vol. 12, Jul. 2024, doi: 10.3389/fbioe.2024.1434465.
X. Shi, K. Zhang, F. Yu, Q. Qi, X. Cai, and Y. Zhang, “Advancements and Innovative Strategies in Induced Pluripotent Stem Cell‐Derived Mesenchymal Stem Cell Therapy: A Comprehensive Review,” Stem Cells Int, vol. 2024, no. 1, Jan. 2024, doi: 10.1155/2024/4073485.
V. Dupuis and E. Oltra, “Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells,” World J Stem Cells, vol. 13, no. 8, pp. 1094–1111, Aug. 2021, doi: 10.4252/wjsc.v13.i8.1094.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Electrical, Computer, and Biomedical Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
